Medical - Vaccine Guide 2022 - 27

Appendix
Vaccine
Haemophilus influenzae type b
(Hib)
Hepatitis A (HepA)
Hepatitis B (HepB)
Hepatitis A- Hepatitis B vaccine
[HepA-HepB, (Twinrix®)]
Human papillomavirus (HPV)
Measles, mumps, rubella (MMR)
Contraindications1
Recommended Adult Immunization Schedule, United States, 2022
Precautions2
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For Hiberix, ActHib, and PedvaxHIB only: History of severe allergic reaction to dry natural latex
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
neomycin
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
yeast
* For Heplisav-B only: Pregnancy
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
neomycin and yeast
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital
immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are
severely immunocompromised)
* Pregnancy
* Family history of altered immunocompetence, unless verified clinically or by laboratory testing as
immunocompetent
Meningococcal ACWY
(MenACWY)
[MenACWY-CRM (Menveo®);
MenACWY-D (Menactra®);
MenACWY-TT (MenQuadfi®)]
Meningococcal B (MenB)
[MenB-4C (Bexsero); MenB-FHbp
(Trumenba)]
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For MenACWY-D and Men ACWY-CRM only: severe allergic reaction to any diphtheria toxoid- or
CRM197-containing vaccine
* For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
Pneumococcal conjugate (PCV15) * Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid-containing vaccine or to its vaccine
component3
Pneumococcal conjugate (PCV20) * Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid- containing vaccine or to its vaccine
component3
Pneumococcal polysaccharide
(PPSV23)
Tetanus, diphtheria, and acellular
pertussis (Tdap)
Tetanus, diphtheria (Td)
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not
attributable to another identifiable cause, within 7 days of administration of previous dose of DTP, DTaP,
or Tdap
* Pregnancy
* For MenB-4C only: Latex sensitivity
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid-containing
vaccine
* History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-
containing or tetanus-toxoid- containing vaccine; defer vaccination until at least 10 years have
elapsed since the last tetanus-toxoid-containing vaccine
* Moderate or severe acute illness with or without fever
* For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive
encephalopathy until a treatment regimen has been established and the condition has stabilized
Varicella (VAR)
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital
immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are
severely immunocompromised)
* Pregnancy
* Family history of altered immunocompetence, unless verified clinically or by laboratory testing as
immunocompetent
Zoster recombinant vaccine (RZV)
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on
product)
* Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination
(avoid use of these antiviral drugs for 14 days after vaccination)
* Use of aspirin or aspirin-containing products
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Current herpes zoster infection
1. When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
2. When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General
Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
3. Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines
are available at www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states.
22MS6015
27
henryschein.com/medical
including
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on
product)
* History of thrombocytopenia or thrombocytopenic purpura
* Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
including
including
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html http://www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states http://www.henryschein.com/medical
Medical - Vaccine Guide 2022

Table of Contents for the Digital Edition of Medical - Vaccine Guide 2022
